BBBlake W. Buchan

Blake W. Buchan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Blake W. Buchan has a total of 355 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antimicrobial and diagnostic stewardship: opportunities for return on investment

    by Tracy Zembles, Blake Buchan, Katie Ray, Michelle Mitchell, Kelly Graff

    Objective: Implementation of antimicrobial and diagnostic stewardship interventions can offer substantial return on investment while enhancing patient safety and healthcare quality. Clinical benefits include a decrease in antimicrobial resistance, shorter hospital stays, fewer adverse events from unnecessary antibiotic use, and optimized treatment protocols. We aimed to estimate the annual cost savings resulting from various interventions implemented by our Antimicrobial Stewardship Program at a single free-standing children’s hospital. Design: Cost analysis. Setting: Free-standing children’s hospital. Patients: Hospitalized patients. Methods: We reviewed annual cost savings related to various targeted antimicrobial and diagnostic stewardship initiatives, including drug cost savings from guidelines and protocols, prevention of antimicrobial resistance, diagnostic stewardship interventions, penicillin allergy de-labeling, and sustainability efforts. Institution-level cost data were evaluated when feasible. Otherwise, cost estimates were extrapolated from the literature. Results: The Antimicrobial Stewardship Program saved an estimated $4,972,805 annually. This was a result of $1,155,405 in direct drug cost savings, $2,953,216 in savings related to a decrease in multi-drug resistant organisms, $75,000 in savings from penicillin allergy de-labeling, $689,184 in savings related to diagnostic stewardship interventions, and $100,000 in savings from sustainability efforts. Conclusions: Antimicrobial Stewardship Programs can be associated with significant cost savings, justifying the investment. Collaboration across departments, particularly with microbiology, pharmacy, infection prevention, and service providers is central to the ongoing success of stewardship efforts, underscoring the multidisciplinary strength and efficiency of the approach.

  • Open Access

    High-throughput multiplex detection of respiratory pathogens: multicenter evaluation of the NxTAG Respiratory Pathogen Panel v2 assay

    by Marisa C. Nielsen, Ping Ren, Sri Bharathi Kavuri, Karissa Culbreath, Rangaraj Selvarangan, Dithi Banerjee, Blake W. Buchan, Rachel Behounek, Janet Farhang

    Respiratory tract infections remain a major cause of global morbidity, highlighting the need for rapid and accurate diagnostic testing. This multicenter study evaluated the clinical and analytical performance of the updated NxTAG Respiratory Pathogen Panel v2 (RPPv2), a high-throughput multiplex molecular assay designed to detect 21 viral and bacterial respiratory pathogens. A total of 2,145 nasopharyngeal swab specimens, including both prospectively enrolled and archived specimens, were analyzed across five U.S. clinical sites. The NxTAG RPPv2 was assessed against FDA-cleared molecular assays and bi-directional sequencing, with contrived specimens used to supplement low-prevalence targets. Valid results were obtained for 99.7% of specimens after a single retest, with minimal performance differences between fresh and frozen specimens. Among viral targets, 15 of 18 (one viral target did not have clinical positive specimens for analysis) achieved ≥95% positive percent agreement (PPA) across the prospective and pre-selected arms. For bacterial targets, Mycoplasma pneumoniae and Chlamydia pneumoniae showed PPA values of 92.3% and 100%, respectively. Lower PPA values were observed for parainfluenza 4 (90.3%). Negative percent agreement (NPA) was consistently high across targets, with all viral and bacterial analytes achieving ≥99.2%. Reproducibility across sites and operators was 99.9%. Overall, the NxTAG RPPv2 demonstrated high accuracy, reproducibility, and operational efficiency, supporting its clinical utility for rapid and reliable diagnosis of respiratory tract infections. IMPORTANCE: Respiratory infections remain a major global health challenge, particularly during seasonal epidemics and pandemics. Rapid and accurate pathogen detection is essential to guide treatment decisions, limit transmission, and reduce unnecessary antibiotic use. This multicenter study evaluated the updated NxTAG Respiratory Pathogen Panel v2 (RPPv2), a high-throughput molecular assay capable of detecting 22 common viral and bacterial respiratory pathogens from a single sample. The panel demonstrated high accuracy, reproducibility, and reliability across multiple clinical sites and sample types, including both fresh and frozen specimens. These findings support the NxTAG RPPv2 as a comprehensive, efficient diagnostic tool that can support respiratory infection diagnosis and contribute to multifaceted antimicrobial stewardship efforts.


  • Open Access

    Comparative evaluation of Savanna HSV 1+2/VZV multiplex assay and Simplexa HSV 1&2 and VZV direct kits for rapid molecular detection of HSV-1, HSV-2, and VZV

    by Blake W. Buchan, Paul A. Granato, Jessica S. Hoff, Marie Wisniewski, Adam Nielsen, Lavannya Sabharwal, Derek Gerstbrein, Amorina Purpora, Puspa Bhattarai, Julie O'NEill, et al.

    Herpes simplex virus (HSV-1 and HSV-2) and varicella-zoster virus (VZV) cause cutaneous and mucocutaneous lesions. Primary infection and secondary reactivations affect the mouth, genitalia, and dermis at other bodily regions. Accurate clinical diagnosis without laboratory confirmation can be difficult since lesions caused by these viruses are nondescript, and areas of bodily infection can overlap. Rapid molecular test results have been shown to reduce the time to definitive diagnosis, providing additional opportunities for patient counseling, antiviral therapy, and appropriate infection prevention measures. A molecular, multiplexed HSV + VZV assay allows both viruses to be tested simultaneously from a single lesion swab. This could potentially enhance diagnostic accuracy through laboratory confirmation, thus minimizing dependence on clinical judgment alone. The recently Food and Drug Administration (FDA)-approved Savanna HSV 1+2/VZV multiplex assay has not been widely evaluated against other FDA-approved assays. This is the first report evaluating the clinical performance of the Savanna HSV 1+2/VZV assay compared to independent assays for HSV and VZV. Results indicated that the Savanna HSV 1+2/VZV assay was comparable to the Diasorin Simplexa HSV 1&2 Direct and VZV Direct assays. IMPORTANCE: Lesion-causing viruses, herpes simplex (HSV-1 and HSV-2) and varicella-zoster virus (VZV), are common and difficult to distinguish clinically. Each can be found over any area of the body but have different treatment regimens and considerations for infectivity and future outbreak management. Laboratory analysis by molecular assay is the gold standard for these viruses, but it can take hours to days and is reliant on the clinician choosing the correct virus to test the first time, or risk being outside the treatment window. A rapid molecular assay that detects all three viruses simultaneously was developed and recently approved by the Food and Drug Administration (FDA). Here, we provide data highlighting the clinical performance of the Savanna HSV 1+2/VZV assay and its ability to detect across anatomical locations and ages. These data indicate that the Savanna assay is comparable to individual assays for each viral target, providing the opportunity for enhanced diagnostic accuracy of lesions.

  • Open Access

    What you see is not always what you get: the influence of epidemiology on ordering practices for herpes simplex virus and varicella zoster virus

    by Blake W. Buchan, Preeti Pancholi

    Background: Herpes simplex virus (HSV) and varicella zoster virus (VZV) are common causes of clinically indistinguishable lesions. The epidemiology and clinical presentation, including anatomic site of lesion and patient age, differ between these viruses, which may influence physician ordering practices. Importantly, atypical presentation of either HSV or VZV can result in the potential for misdiagnosis or missed diagnosis. Case Summary: Two cases are presented illustrating atypical anatomic location and presentation of HSV-1 and VZV lesions that resulted in failure to consider the virus when placing orders for laboratory testing, leading to missed or misdiagnosis. Conclusion: Atypical presentation of HSV or VZV resulting in failure to order the appropriate laboratory test impacts a significant minority of cases, which can lead to failure to prescribe appropriate therapy, extended symptoms, and additional interaction with the healthcare system.


  • Open Access

    Longitudinal Gut Microbiome Changes Associated with Transitions from C. difficile Negative to C. difficile Positive on Surveillance Tests

    by L. Silvia Munoz-Price, Samantha N. Atkinson, Vy Lam, Blake Buchan, Nathan Ledeboer, Nita H. Salzman, Amy Y. Pan

    Clostridioides difficile is an obligate anaerobe and is primarily transmitted via the fecal–oral route. Data characterizing the microbiome changes accompanying transitions from non-colonized to C. difficile colonized subjects are currently lacking. In this retrospective cohort study, we examined 16S rRNA gene sequencing data in a total of 481 fecal samples belonging to 107 patients. Based on C. difficile status over time, patients were categorized as Negative-to-Positive, Negative Control, and Positive Control. A linear mixed effects model was fitted to investigate the changes in the Shannon α-diversity index over time. Zero-inflated negative binomial/Poisson mixed effects models or generalized linear mixed models with negative binomial/Poisson distribution were used to investigate the changes in taxon counts over time among different groups. A total of 107 patients were eligible for the study. The median number of stool samples per patient was 3 (IQR 2–4). A total of 42 patients transitioned from C. difficile negative to positive (Negative-to-Positive), 47 patients remained negative throughout their tests (Negative Control) and 18 were always C. difficile positive (Positive Control). A significant difference in microbiome composition between the last negative samples and the first positive samples were shown in Negative-to-Positive patients, ANOSIM p = 0.022. In Negative-to-Positive patients, the phylum Pseudomonadota and family Enterobacteriaceae increased significantly in the first positive samples compared to the last negative samples, p = 0.0075 and p = 0.0094, respectively. Within the first 21 days, Actinomycetota decreased significantly over time in the Positive Control group compared to the other two groups (p < 0.001) while Bacillota decreased in both the Negative-to-Positive group and Positive Control. These results demonstrate that the transition from C. difficile negative to C. difficile positive is associated with alterations in gut microbial communities and their compositional patterns over time. Moreover, these changes play an important role in both the emergence and intensification of the gut microbiome dysbiosis in patients who transitioned from C. difficile negative to positive and those who always tested positive.


  • When less is more: the art of communicating clinical microbiology results

    by Blake W. Buchan

    The clinical microbiology laboratory is capable of identifying microorganisms in clinical specimens faster and more accurately than ever before. At face value, this should enable patient care providers to make better-informed decisions and target antimicrobial therapies to deliver individualized care. Ironically, more complete and specific reporting of microorganisms isolated from specimens may result in overtreatment based on the presence of a pathogen, even in the absence of clear signs of clinical infection. This conundrum calls into question the role of the laboratory in contributing to care through selective or “exception” reporting whereby some results are selectively withheld when there is a low probability that laboratory findings correlate with the clinical infection. In a recent article published in the Journal of Clinical Microbiology , Bloomfield et al. (J Clin Microbiol 62:e00342-24, 2024, https://doi.org/10.1128/jcm.00342-24 ) examine the impact and safety of an exception reporting strategy applied to wound swab specimens. Canonical pathogens associated with skin and soft tissue infections including S. aureus and beta-hemolytic streptococci are withheld from the laboratory report if certain patient criteria are met that would put them at low risk of adverse outcomes if untreated, or if treated with guideline-recommended empiric therapy. Their central finding was an approximately 50% reduction in post-laboratory report antibiotic initiation without adverse events or increased 30-day admission rate (indicative of infection-related complications, e.g., disseminated disease). While effectively achieving their goal, the premise of exception reporting and other modified reporting strategies raises questions about the potential risk of underreporting and how to ensure that the message is being interpreted, and acted upon, by care providers as was intended by the laboratory.


  • Open Access

    Comparison of the Simplexa GBS Direct and ARIES GBS assays for the detection of S. agalactiae in broth-enriched swab specimens

    by Lavannya Sabharwal, Matthew L. Faron, Blake W. Buchan

    We conducted a comparative evaluation of the FDA-cleared Simplexa GBS Direct and ARIES GBS molecular assays for the detection of Streptococcus agalactiae (Group B Streptococcus , GBS) in 386 prospectively collected, broth-enriched vaginal/rectal swab specimens. The sensitivity of each test was 96.2% and specificity was ≥98.7% when compared to a combined direct and enriched culture method using chromogenic culture medium. A total of four specimens were called positive by both molecular assays but negative by culture, likely representing specimens with a low burden of GBS in these specimens. Two specimens were reported positive by culture but negative by both molecular assays. One of these specimens demonstrated atypically colored colonies on chromogenic agar; the other yielded typically colored colonies only observed after broth enrichment. Our data demonstrate equivalent performance of Simplexa and ARIES molecular assays for the detection of GBS in clinical specimens. IMPORTANCE: Clinical laboratories often face decisions regarding which of the multiple available molecular platforms would best fit their needs based on cost, workflow, menu, and diagnostic performance. Therefore, objective clinical comparisons of similar molecular tests are valuable resources to aid these decisions. We provide a clinical comparison of two FDA-cleared tests to routine culture and to each other that can be used by clinical laboratories when determining which of the available molecular platforms would best fit their laboratory in terms of workflow, cost, and performance.


  • Open Access

    Multiplex High-Definition Polymerase Chain Reaction Assay for the Diagnosis of Tick-borne Infections in Children

    by Lise E Nigrovic, Desiree N Neville, Laura Chapman, Fran Balamuth, Michael N Levas, Amy D Thompson, Anupam B Kharbanda, Derek Gerstbrein, John A Branda, Blake W Buchan, et al.

    Ixodes scapularis ticks can carry Borrelia species as well as other pathogens that cause human disease. The frequency of tick-borne infections and coinfections in children with suspected Lyme disease is unknown, creating clinical uncertainty about the optimal approach to diagnosis. We enrolled children aged 1–21 years presenting to 1 of 8 Pedi Lyme Net emergency departments for evaluation of Lyme disease. We selected cases with serologically or clinically diagnosed Lyme disease (erythema migrans or early neurologic disease) matched by symptoms, age, gender, and center to control subjects without Lyme disease. We tested whole blood samples collected at the time of diagnosis using a multiplex high-definition polymerase chain reaction (HDPCR) panel to identify 9 bacterial or protozoan pathogens associated with human disease. We compared the frequency of tick-borne coinfections in children with Lyme disease to matched controls. Of the 612 selected samples, 594 (97.1%) had an interpretable multiplex HDPCR result. We identified the following non-Borrelia tick-borne infections: Anaplasma phagocytophilum (2), Ehrlichia chaffeensis (1), and Babesia microti (12). Children with Lyme disease were more likely to have another tick-borne pathogen identified than matched controls (15/297 [5.1%] Lyme cases vs 0/297 [0%]; difference, 5.1% [95% confidence interval, 2.7%–8.2%]). Although a substantial minority of children with Lyme disease had another tick-borne pathogen identified, either first-line Lyme disease antibiotics provided adequate treatment or the coinfection was subclinical and did not require specific treatment. Further studies are needed to establish the optimal approach to testing for tick-borne coinfections in children.


  • Commentary: Can Automated Blood Culture Systems Be Both New and Improved?

    by Blake W. Buchan

    Automated continuous monitoring blood culture (CMBC) systems are a cornerstone of the clinical microbiology laboratory. Despite the critical role of these systems in diagnosing life-threatening bloodstream infections, their core technologies and performance characteristics have remained largely unchanged since their introduction in the 1990s.


  • Open Access

    A Multicenter Clinical Study To Demonstrate the Diagnostic Accuracy of the GenMark Dx ePlex Blood Culture Identification Gram-Negative Panel

    by Donna M. Wolk, Stephen Young, Natalie N. Whitfield, Jennifer L. Reid, Adam Thornberg, Karen C. Carroll, Blake W. Buchan, Thomas E. Davis, Hossein Salimnia

    Bacteremia can progress to septic shock and death without appropriate medical intervention. Increasing evidence supports the role of molecular diagnostic panels in reducing the clinical impact of these infections through rapid identification of the infecting organism and associated antimicrobial resistance genes.